The Experts below are selected from a list of 14754 Experts worldwide ranked by ideXlab platform
Sebastian Leptihn - One of the best experts on this subject based on the ideXlab platform.
-
Secondary Bacterial Infections in Patients With Viral Pneumonia
Frontiers in medicine, 2020Co-Authors: Prasanth Manohar, Belinda Loh, Ramesh Nachimuthu, Xiaoting Hua, Susan C. Welburn, Sebastian LeptihnAbstract:Pulmonary diseases of Viral origin are often followed by the manifestation of secondary infections, leading to further clinical complications and negative disease outcomes. Thus, research on secondary infections is essential. Here, we review clinical data of secondary bacterial infections developed after the onset of pulmonary Viral infections. We review the most recent clinical data and current knowledge of secondary bacterial infections and their treatment in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied respiratory virus, influenza, are described. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This evaluation includes recent clinical reports of pulmonary Viral infections, including those by COVID-19, that reference secondary infections. Where data was provided for COVID-19 patients, a mortality rate of 15.2% due to secondary bacterial infections was observed for patients with Pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2 infections with prophylactic antibiotics (63.7%, n = 1,901), compared to 73.5% (n = 3,072) in all clinical reports of Viral Pneumonia included in this review. For all cases of Viral Pneumonia, a mortality rate of 10.9% due to secondary infections was observed (53 of 482). Most commonly, quinolones, cephalosporins and macrolides were administered, but also the glycopeptide vancomycin. Several bacterial pathogens appear to be prevalent as causative agents of secondary infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella Pneumoniae.
Hui Lui - One of the best experts on this subject based on the ideXlab platform.
-
Effects and safety of Tanreqing injection on Viral Pneumonia: A protocol for systematic review and meta-analysis.
Medicine, 2020Co-Authors: Yue Qiu, Xue Pan, Hui LuiAbstract:Influenza-related Viral Pneumonia is a severe threat to human health, which has caused high morbidity and mortality each year. The objective of this study was to assess the efficacy and safety of Tanreqing Injection therapy in patients with Viral Pneumonia. This protocol established in this study has been reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. Web of Science, PubMed, EMBASE and the Cochrane Library were searched for clinical randomized trials in cases with Viral Pneumonia until 1st of July 2020. We will use a combination of Medical Subject Heading and free-text terms with various synonyms to search based on the Eligibility criteria. Two investigators independently reviewed the included studies and extracted relevant data. The relative risk (RR) and 95% confidence intervals (CIs) of were used as effect estimate. I-square (I) test, substantial heterogeneity, sensitivity analysis and publication bias assessment will be performed accordingly. Stata 14.0 and Review Manger 5.3 are used for meta-analysis and systematic review. The results will be published in a peer-reviewed journal. The results of this review will be widely disseminated through peer-reviewed publications and conference presentations. This evidence may also provide helpful evidence of whether Tanreqing Injection therapy was efficient and safe in patients with Viral Pneumonia. CRD42020164164.
Yi Wang - One of the best experts on this subject based on the ideXlab platform.
-
Effects and safety of tanreqing injection on Viral Pneumonia: A protocol for systematic review and meta-analysis.
Medicine, 2020Co-Authors: Hui Liu, Xue-fei Ding, Rui Guo, Meng-fan Zhao, Di Deng, Yu Hao, Yi WangAbstract:Background Viral Pneumonia is a common respiratory disease that leads to high mortality around the world. Tanreqing (TRQ) injection has been widely used to treat Viral Pneumonia in China. However, the efficiency and safety of TRQ injection for Viral Pneumonia have not been scientifically and methodically evaluated up to now. Thus, this protocol describes a plan of performing a systematic review and meta-analysis to evaluate the efficacy and safety of TRQ injection on patients with Viral Pneumonia. Methods Only randomized controlled trials will be enrolled in our study, and we will search eligible studies in the following electronic databases: PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trials, China National Knowledge Infrastructure, the Wanfang database, the Chinese Scientific Journal Database, and the Sinomed. The total effective rate of clinical efficacy will be used as primary outcome. Time to relieve symptoms, incidence of adverse reactions, and the laboratory parameters will be used as secondary outcomes. Any side effects and adverse events will be recorded and assessed as safety outcomes. Study inclusion, data extraction, and quality assessment will be performed independently by 2 reviewers, and any disagreement will be resolved by a third reviewer. After that, data synthesis and subgroup analysis will be conducted with the Review Manager V.5.3.3 software. Results This review will provide a high-quality synthesis to assess the effectiveness and safety of TRQ injection for Viral Pneumonia patients. Conclusion Our study will provide comprehensive evidence to decide whether TRQ injection is effective and safe for Viral Pneumonia patients. Prospero registration number PROSPERO CRD42020164164.
Prasanth Manohar - One of the best experts on this subject based on the ideXlab platform.
-
Secondary Bacterial Infections in Patients With Viral Pneumonia
Frontiers in medicine, 2020Co-Authors: Prasanth Manohar, Belinda Loh, Ramesh Nachimuthu, Xiaoting Hua, Susan C. Welburn, Sebastian LeptihnAbstract:Pulmonary diseases of Viral origin are often followed by the manifestation of secondary infections, leading to further clinical complications and negative disease outcomes. Thus, research on secondary infections is essential. Here, we review clinical data of secondary bacterial infections developed after the onset of pulmonary Viral infections. We review the most recent clinical data and current knowledge of secondary bacterial infections and their treatment in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied respiratory virus, influenza, are described. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This evaluation includes recent clinical reports of pulmonary Viral infections, including those by COVID-19, that reference secondary infections. Where data was provided for COVID-19 patients, a mortality rate of 15.2% due to secondary bacterial infections was observed for patients with Pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2 infections with prophylactic antibiotics (63.7%, n = 1,901), compared to 73.5% (n = 3,072) in all clinical reports of Viral Pneumonia included in this review. For all cases of Viral Pneumonia, a mortality rate of 10.9% due to secondary infections was observed (53 of 482). Most commonly, quinolones, cephalosporins and macrolides were administered, but also the glycopeptide vancomycin. Several bacterial pathogens appear to be prevalent as causative agents of secondary infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella Pneumoniae.
Tengxiao Liang - One of the best experts on this subject based on the ideXlab platform.
-
Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.
Frontiers in pharmacology, 2020Co-Authors: Lifeng Yue, Yuewen Gong, Linchao Qian, Tengxiao LiangAbstract:Viral Pneumonia is one kind of acute respiratory tract infection caused by the virus. There have been many outbreaks of Viral Pneumonia with high contagiousness and mortality both in China and abroad, such as the great influenza in 1918, the severe acute respiratory syndrome (SARS) coronavirus in 2003, the Influenza A (H1N1) virus in 2009, and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012 and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. These outbreaks and/or pandemic have significant impact on human life, social behaviors, and economic development. Moreover, no specific drug has been developed for these viruses. Traditional Chinese medicine (TCM) plays an important role in the treatment of Viral Pneumonia during these outbreaks especially in SARS and SARS-CoV-2 because studies suggest that TCM formulations may target several aspects of the disease and may have lesser side effects than manufactured pharmaceuticals. In recent years, a lot of clinicians and researchers have made a series of in-depth explorations and investigations on the treatment of Viral Pneumonia with TCM, which have understood TCM therapeutic mechanisms more specifically and clearly. But critical analysis of this research in addition to further studies are needed to assess the potential of TCM in the treatment of Viral Pneumonia.
